Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).
Patients ≥18 years of age, with biopsy confirmed MPM and histological subtyping (epithelioid or non-epithelioid)
N0 or N1 and M0 disease
Written informed consent
Patient and local/regional MDT opt for active surveillance and deferral of SACT until clinical or radiological progression
Presence of metastatic or contralateral disease
Cytological diagnosis and/or undetermined histological subtype
Prior thoracic radiotherapy, chemotherapy, immunotherapy for MPM
Prior radical surgery for MPM (extrapleural pneumonectomy or extended pleurectomy decortication or pleurectomy decortication)
University College, London
Lead sponsor
Asthma + Lung UK
Collaborator
Mesothelioma UK
Collaborator
University of Sheffield
Collaborator